Search results
Showing 7681 to 7695 of 7708 results
NICE recommends several treatment options to help with rheumatoid arthritis
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.
NICE recommends range of treatments for people with chronic primary pain
People with chronic primary pain should be offered a range of treatments to help them manage their condition.
NICE recommends treatment for people with short bowel syndrome
A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged 1 year and above.
NICE recommends offering PrEP to people at high risk of HIV for first time
People at the highest risk of catching HIV should be offered Pre Exposure Prophylaxis (PrEP), NICE has recommended for the first time.
New treatment option for adults with obesity and non-diabetic hyperglycaemia
All eligibility criteria must be met for Liraglutide to be offered.
Children and young people need accurate, accessible information about their healthcare
New draft guidance from NICE recommends children and young people are fully informed about their health so that they can take an active role in their healthcare.
Avelumab not recommended as a maintenance treatment of urothelial cancer
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
NICE recommends new diagnostic devices for men with suspected prostate cancer in draft guidance
Four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related sepsis, have been recommended for use by NICE.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
More than 1,000 people each year will benefit from NICE's recommendation.
NICE recommends innovative treatment for severe blood disorder for NHS use
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
People with a rare blood disorder have access to a new treatment following draft guidance from NICE.
NICE recommends 'game changing' histology independent cancer drug
Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).
NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.
Two new antimicrobial drugs are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model.